Suppr
超能文献

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.

作者信息

Popat Sanjay, Vieira de Araújo Alexandra, Min Toon, Swansbury John, Dainton Melissa, Wotherspoon Andrew, Lim Eric, Nicholson Andrew G, O'Brien Mary E R

机构信息

Royal Marsden Hospital, London and Surrey, United Kingdom.

出版信息

J Thorac Oncol. 2011 Nov;6(11):1962-3. doi: 10.1097/JTO.0b013e31822eec5e.

DOI:10.1097/JTO.0b013e31822eec5e

PMID:22005476

Abstract

摘要

相似文献

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.

J Thorac Oncol. 2011 Nov;6(11):1962-3. doi: 10.1097/JTO.0b013e31822eec5e.

An uncommon insertion mutation in exon 19 of EGFR showed stable disease after TKI treatment.

J Thorac Oncol. 2013 Dec;8(12):e107-8. doi: 10.1097/JTO.0b013e3182a471e0.

First case of A859T epidermal growth factor receptor mutation responding to erlotinib.

J Thorac Oncol. 2011 Mar;6(3):639-40. doi: 10.1097/JTO.0b013e3182037c0c.

Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.

J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095.

Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.

J Thorac Oncol. 2008 Apr;3(4):451-2. doi: 10.1097/JTO.0b013e318169e32a.

Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.

J Thorac Oncol. 2011 Nov;6(11):1895-901. doi: 10.1097/JTO.0b013e318227e8c6.

Favorable response to erlotinib in a lung adenocarcinoma with both epidermal growth factor receptor exon 19 deletion and K-ras G13D mutations.

J Clin Oncol. 2010 Mar 1;28(7):e111-2. doi: 10.1200/JCO.2009.24.0747. Epub 2009 Dec 14.

Two rare exon 21 EGFR mutations in patients treated with gefitinib.

J Thorac Oncol. 2013 Apr;8(4):e36-7. doi: 10.1097/JTO.0b013e318286cf9e.

Two generations of light/never-smokers with advanced adenocarcinoma of the lung with durable responses to erlotinib.

J Thorac Oncol. 2012 Jul;7(7):1200-1. doi: 10.1097/JTO.0b013e318250ed89.

Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.

J Thorac Oncol. 2014 May;9(5):e37-9. doi: 10.1097/JTO.0000000000000097.

引用本文的文献

Comparing Genomic Profiles of Fusion-Positive and Fusion-Negative Nonsmall Cell Lung Cancer Patients.

Glob Med Genet. 2024 Jun 13;11(2):175-186. doi: 10.1055/s-0044-1787301. eCollection 2024 Jun.

Case report: Concomitant mutation and rearrangement in non-small cell lung cancer.

Front Pharmacol. 2023 Aug 29;14:1167959. doi: 10.3389/fphar.2023.1167959. eCollection 2023.

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling.

NPJ Precis Oncol. 2022 Nov 11;6(1):84. doi: 10.1038/s41698-022-00325-0.

Analysis of real-word mutations of lung cancer driver genes in five regions of China.

Transl Cancer Res. 2019 Nov;8(7):2581-2592. doi: 10.21037/tcr.2019.10.28.

Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.

Thorac Cancer. 2022 Feb;13(4):637-642. doi: 10.1111/1759-7714.14291. Epub 2021 Dec 28.

Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.

BMC Cancer. 2021 Oct 15;21(1):1107. doi: 10.1186/s12885-021-08824-2.

Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma-a case report and a literature review.

Porto Biomed J. 2021 Feb 11;6(1):e124. doi: 10.1097/j.pbj.0000000000000124. eCollection 2021 Jan-Feb.

Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors.

Front Oncol. 2021 Jan 15;10:544579. doi: 10.3389/fonc.2020.544579. eCollection 2020.

Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.

Diagn Pathol. 2020 May 6;15(1):42. doi: 10.1186/s13000-020-00969-1.

Incidence of -Rearranged Non-Small-Cell Lung Carcinoma in India and Efficacy of Crizotinib in Lung Adenocarcinoma Patients.

Lung Cancer (Auckl). 2020 Feb 24;11:19-25. doi: 10.2147/LCTT.S244366. eCollection 2020.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译